After much criticism and disqualification of one of the
drugs, promoted by the President of the United States, Donald Trump, to treat
COVID19, today the most advanced nations have reported having enough medication
to face the new cases that are registered in those countries.
Some governments in Europe and Asia said Wednesday that they
already have enough of Gilead's antiviral remdesivir to treat COVID-19 for now,
despite fears of a shortage after the US drug maker promised most of its
production to the market. internal in the next three months.
The pharmaceutical company's move has sparked global debate
about equal access to medicines and concerns about access to medicines,
especially in regions where coronavirus rates remain high or where new
outbreaks have been seen.
Remdesivir is in high demand after the intravenous drug
helped shorten hospital recovery times in a clinical trial. It is believed to
be more effective in treating patients with COVID-19 at an earlier stage of the
disease than other therapies such as the steroid dexamethasone.
Post a Comment
We want to know your comments and concerns. Remember: Respect distinguishes us, education makes us different...